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Low-dose cisplatin and 5-fluorouracil (LDPF) chemotherapy with daily radiotherapy
(RT) is used as an alternative chemoradiotherapy regimen for locally advanced
esophageal carcinoma. We evaluated whether RT plus LDPF chemotherapy had an
advantage in terms of survival and ⁄or toxicity over RT plus standard-dose cisplatin
and 5-fluorouracil (SDPF) chemotherapy in this study. This multicenter trial included
esophageal cancer patients with clinical T4 disease and ⁄or unresectable regional
lymph node metastasis. Patients were randomly assigned to receive RT (2 Gy ⁄ frac-
tion, total dose of 60 Gy) with SDPF (arm A) or LDPF (arm B) chemotherapy. The pri-
mary endpoint was overall survival (OS). A total of 142 patients (arm A ⁄ B, 71 ⁄ 71)
from 41 institutions were enrolled between April 2004 and September 2009. The
OS hazard ratio in arm B versus arm A was 1.05 (80% confidence interval, 0.78–
1.41). There were no differences in toxicities in either arm. Arm B was judged as
not promising for further evaluation in the phase III setting. Thus, the Data and
Safety Monitoring Committee recommended that the study be terminated. In the
updated analyses, median OS and 3-year OS were 13.1 months and 25.9%, respec-
tively, for arm A and 14.4 months and 25.7%, respectively, for arm B. Daily RT plus
LDPF chemotherapy did not qualify for further evaluation as a new treatment
option for patients with locally advanced unresectable esophageal cancer. This
study was registered at the UMIN Clinical Trials Registry as UMIN000000861.
C arcinoma of the esophagus is an extremely devastatingdisease, especially when the cancer is unresectable (direct
invasion of adjacent organs; cT4). According to the Compre-
hensive Registry of Esophageal Cancer in Japan, the incidence
of cT4 esophageal carcinoma is approximately 15% among all
esophageal cancer patients.(1) Curative resection is not feasible
in patients with locally advanced esophageal cancer, particu-
larly cT4 cancer, and such cases have an unfavorable
prognosis.(2–5) Definitive chemoradiotherapy (CRT) without
planned esophagectomy is one of the most attractive treatment
options currently available for locally advanced esophageal
cancer.(4–6)
The combination of cisplatin and 5-fluorouracil (5-FU) is
currently a standard chemotherapy for esophageal cancer. In
Japan, the standard treatment regimen consists of two courses
of chemotherapy with cisplatin (70 mg ⁄m2 on days 1 and 29)
and 5-FU (700 mg ⁄m2 on days 1–4 and 29–32) administered
concurrently with radiotherapy (RT). This widely used regimen
is based on the results of a Japan Clinical Oncology Group
(JCOG) study (JCOG9516).(4) Despite a lack of sufficient evi-
dence, RT plus low-dose cisplatin and 5-FU (LDPF) is thought
to be an alternative regimen. This regimen is believed to have
equivalent efficacy to RT plus standard-dose cisplatin and
5-FU (SDPF), with a low incidence of severe toxicity and the
potential to permit cessation of concurrent chemotherapy
before severe adverse events occur. The LDPF regimen is
thought to be both a radiosensitizer and a biochemical modula-
tor.(7–9) Therefore, reports have suggested that LDPF-RT
would be more effective than SDPF-RT because of biochemi-
cal modulation.
We hypothesized that LDPF-RT is more effective and less
toxic than SDPF-RT in patients with locally advanced, unre-
sectable esophageal carcinoma. Because we did not have suffi-
cient toxicity information regarding LDPF-RT at the time this
study was planned, we prepared a phase II component within
the phase III trial to determine whether the phase III trial
would be designed as superiority or a non-inferiority trial
(based on the relative toxicities of the two arms). However,
the study was terminated at the end of the phase II component;
we hereby report the final results of this study.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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Patients and Methods
Eligibility. Patients with histologically proven squamous cell,
adenosquamous, or basaloid carcinoma of the thoracic esopha-
gus were eligible if they had had any of the following condi-
tions: definite clinical T4 cancer; at least 1 unresectable
metastatic regional lymph node due to invasion into an adja-
cent organ; or computed tomography (CT) evidence of M1
lymph nodes (M1Lym), such as fixed supraclavicular or celiac
lymph nodes. Regional lymph nodes were defined on the basis
of criteria specified by the 5th edition of the Union for Interna-
tional Cancer Control TNM staging system.(10) Other eligibility
criteria were as follows: no prior chemotherapy and ⁄or RT for
esophageal or any other carcinoma; age 20–75 years; an East-
ern Cooperative Oncology Group performance status (PS) of
0–2; and sufficient organ functions. Patients with an esopha-
geal–mediastinal, esophageal–tracheal, or esophageal–bronchial
fistulae, distant organ metastases, serious complications (such
as ischemic heart disease) within 3 months before registration,
severe infection, or mental disorder, were excluded from the
study. In addition, consultation with an institutional radiation
oncologist was mandatory before enrolment to confirm that
definitive radiotherapy was indicated according to the protocol.
Barium esophagography, esophagoscopy, and CT of the
neck, chest, and abdomen were carried out prior to the study.
Involvement of adjacent organs was determined by CT.
Tumors were considered to be cT4 if they extended into the
lumen or caused a deformity of the airway or if they were
attached to the aorta at a contact angle of >90° in over three
CT slices.(11) This study protocol was approved by the JCOG
Clinical Trial Review Committee and the institutional review
boards of the participating institutions. Written informed con-
sent was obtained from all patients prior to enrollment. This
study was registered with the UMIN Clinic Trials Registry
(http://www.umin.ac.jp/ctr/), identification number
UMIN000000861.
Treatment. The patients were randomized to receive either
SDPF-RT (arm A) or LDPF-RT (arm B). Chemotherapy in arm
A consisted of 70 mg ⁄m2 cisplatin given on days 1 and 29 com-
bined with a continuous infusion of 700 mg ⁄m2 5-FU given on
days 1–4 and 29–32. Arm B received a 1-h infusion of 4 mg ⁄m2
cisplatin before RT, combined with a continuous infusion of
200 mg ⁄m2 5-FU on the first 5 days of each week. Treatment
completion was defined as termination of two courses of chemo-
therapy and 60 Gy radiotherapy within 63 days.
Radiotherapy using megavoltage equipment was started on
day 1 concomitantly with chemotherapy in both groups.
Radiotherapy was prescribed to a total dose of 60 Gy in 30
fractions, and the overall treatment period was limited to 40–
63 days. For treatment planning, both conventional 2-D X-ray
simulation and 3-D CT simulation were allowed. The gross
tumor volume was defined as the volume of the primary tumor
as indicated on CT scan and ⁄ or endoscopy and any metastatic
lymph nodes measuring ≥1 cm in greatest dimension. For this
trial, the clinical target volume (CTV) for the primary tumor
was created to add a 2-cm margin craniocaudally to account
for subclinical tumor extension. A CTV margin for metastatic
lymph nodes was not added, and the CTV did not include
elective irradiation of regional lymph nodes. The planning tar-
get volume was defined by adding margins to the CTV at the
discretion of the treating radiation oncologists (typically 0.5–
1 cm for lateral margins and 1–2 cm for craniocaudal margins,
depending on respiratory motion and patient immobilization
technique). A dose of 60 Gy to the center of the planning
target volume was prescribed. The dose to the spinal cord was
kept at ≤44 Gy. The doses to the gastric antrum, duodenum
⁄ small intestine, and colon were kept at ≤50 Gy, ≤40 Gy, and
≤45 Gy, respectively. If a tumor was located in the middle or
lower thoracic esophagus, treatment using three to four ports
was recommended to decrease the risk of cardiac toxicity. For
the treatment of tumors in the upper thoracic esophagus and
supraclavicular lymph node metastases, the number of ports
used was left to the discretion of the radiation oncologists.
Assessment. Toxicities were monitored weekly during treat-
ment according to the National Cancer Institute Common Tox-
icity Criteria (version 2.0). Late toxicity was graded according
to the Radiation Therapy Oncology Group ⁄European Organiza-
tion for Research and Treatment of Cancer late radiation mor-
bidity scoring scheme. Late toxicity was defined as toxicity
occurring more than 31 days after treatment completion.
Primary tumor response was evaluated by endoscopy using
the modified criteria of the Japanese Society for Esophageal
Diseases. Complete response (CR) was defined when both pri-
mary tumors and lymph node metastases disappeared without
the presence of ulceration or malignant cells in biopsy speci-
mens at the first evaluation after CRT. Patients with CR were
followed without treatment on the basis of post-treatment eval-
uation. If recurrence was noted after treatment, surgical resec-
tion was considered if possible.
Radiotherapy quality assurance review was carried out in
this study, and the results have been reported elsewhere.(12)
Statistical methods. The primary endpoint was overall sur-
vival (OS), and the secondary endpoints were the proportion
of CR (%CR), the proportion of treatment completion by PS,
and toxicity. After confirmation of eligibility criteria, patients
were randomly assigned to either arm A (SDPF-RT) or arm B
(LDPF-RT) at the JCOG Data Center. A minimization method
was used to balance clinical T status (cT4 vs cT1–3), PS (East-
ern Cooperative Oncology Group 0 vs 1 vs 2), and institution.
This study was designed as an adaptive phase II ⁄ III trial in
which the purpose of the phase II component was to evaluate
for futility and to determine the study design of the phase III
component. If arm B (LDPF-RT) was inferior to arm A
(SDPF-RT) with a one-sided significance level of 0.1 in the
phase II component, this study was to be terminated due to
futility. In addition, the toxicities of both arms were evaluated
at the conclusion of the phase II component. The phase III
component was to be a superiority trial if arm B was proven
to be more toxic than arm A in the phase II component,
whereas it was to be a non-inferiority trial if arm B was less
toxic than arm A.
The planned sample size in the phase II component was 110
or more to detect a hazard ratio of 1.6 with a one-sided alpha
of 0.1 and power of at least 0.85. Assuming a non-inferiority
design at the planning of this study, the planned sample size in
phase III was 364 patients (including phase II patients) with a
power of 80%, a one-sided alpha of 5%, an expected 1-year
OS of 40%, and a non-inferiority margin of 1.31 for the hazard
ratio. The planned accrual was 4 years, and the follow-up per-
iod was 1 year. Overall survival was calculated from the date
of randomization to the date of death from any cause and was
censored at the time of last follow-up. Overall survival was
estimated using the Kaplan–Meier method, and comparisons
between the two arms were carried out using the unstratified
log–rank test. Hazard ratios of treatment effects were esti-
mated by using the unstratified Cox regression model. All sta-
tistical analyses were carried out using SAS software, release
9.2 (SAS Institute, Cary, NC, USA).
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Results
Patient randomization. A CONSORT diagram is shown in
Figure 1. Initially, this study included 25 institutions. Ulti-
mately, the number of institutions was increased to 41. During
the period between April 2004 and September 2009, a total of
142 patients were registered. The median number of patients
who were registered in each institution was 2 (range, 0–17).
The median observation time of all patients and survivors were
13.6 and 54.7 months, respectively. Three of 71 patients in
arm A were ineligible. The reasons for ineligibility were: his-
tory of radiation for oropharynx carcinoma, extended target
volume, and irradiation fields that included the small intestine.
Eventually, a total of 139 patients were eligible and were
included in the efficacy analysis; the safety analysis was con-
ducted for 140 treated patients, excluding two untreated
patients (one in each arm).
Patient characteristics. The baseline characteristics of each
arm are shown in Table 1. Histopathological findings from
biopsy specimens of all patients indicated squamous cell carci-
noma. These patients consisted of 1% (142 ⁄14 111) of all
patients with thoracic esophageal carcinoma treated in the par-
ticipating institutions during the study. Thirty-one percent
(142 ⁄ 464) of all patients who met the eligibility criteria agreed
to participate in this study. The characteristics of patients in
both treatment arms were similar.
Treatment completion. Fifty-six of 68 patients (82%) in arm
A and 61 of 71 patients (86%) in arm B completed treatment.
The reasons for treatment termination in arm A and arm B
included tumor progression (2 ⁄3), adverse events (8 ⁄3), patient
refusal associated with adverse events (0 ⁄2), death during
treatment (2 ⁄1), and other reasons (0 ⁄1). The proportion of
treatment completion by PS was as follows: PS0 74% (26 ⁄35)
and 89% (31 ⁄35), PS1 91% (29 ⁄32) and 86% (30 ⁄35), and
PS2 100% (1 ⁄1) and 0% (0 ⁄1) in arm A and arm B, respec-
tively. As a post-therapy, 20 patients (12 in group A and 8 in
group B) underwent surgery for residual or recurrent disease.
Toxicity. Toxicities that occurred during treatment among the
70 treated patients in each arm are listed in Table 2. The pro-
portion of grade 3 or 4 hematological toxicities in arm A and
arm B included leukopenia (26 ⁄21%), neutropenia (19 ⁄7%),
anemia (14 ⁄6%), thrombocytopenia (4 ⁄3%), and hyponatremia
(17 ⁄13%). Other grade 4 hematological adverse events included
elevation of AST (n = 1), elevation of ALT (n = 2), hypernatre-
mia (n = 1), and hyperkalemia (n = 1) in arm A and hypokale-
mia (n = 1) in arm B. The proportion of most common grade 3–
4 non-hematological toxicities in arm A and arm B included
included dysphasia ⁄ esophagitis ⁄ odynophagia (23 ⁄29%), anor-
exia (20 ⁄21%), infection without neutropenia (9 ⁄13%), and fis-
tula formation (9 ⁄7%).
Grade 3–4 late toxicities that occurred 30 days after comple-
tion of treatment in 65 and 68 assessable patients in arm A
and arm B, respectively, included fistula formation (18 ⁄ 22),
dysphasia ⁄ esophagitis ⁄odynophagia (11 ⁄ 10), dyspnea (14 ⁄18),
pneumonitis (9 ⁄9), and pericardial effusion (3 ⁄0) (all percent-
ages), as shown in Table 3.
Grade 3–4 fistula formation occurred frequently in both arms,
affecting 15 patients in arm A and 17 patients in arm B. In total,
fistula formation occurred in 32 of 140 patients (23%) during or
after treatment. Thirteen patients in each arm had cT4 disease
before treatment. Intercurrent deaths occurred in two patients in
arm A and one patient in arm B. The causes of death in arm A
were massive bleeding precipitated by an esophageal–aortic fis-
tula and pneumonia due to an esophageal–pulmonary fistula. In
arm B, the single intercurrent death was caused by massive
bleeding due to an esophageal–tracheal fistula.
Before the analysis of the phase II component, the partici-
pating investigators, while remaining blinded to the efficacy
data for each arm, discussed the advantages and disadvantages
of both arms and concluded that both arms were equally toxic
but that arm B (RT plus LDPF) had disadvantages that
included a longer time spent receiving continuous infusion
chemotherapy and longer hospital stays. Thus, they declared to
the Data and Safety Monitoring Committee that the phase III
component should be a superiority trial of arm B over arm A.
Efficacy. In May 2009, the OS among patients receiving
LDPF-RT was slightly inferior to patients treated with SDPF-
RT (hazard ratio, 1.05; 80% confidence interval [CI], 0.78–
1.41; unstratified one-sided log-rank P for non-inferiority
=0.42). Eventually, the Data and Safety Monitoring Committee
of JCOG recommended that the study be terminated due to
futility rather than moved forward to the phase III component.
The study was therefore terminated after the phase II compo-
nent was completed.
In the updated analyses in November 2011, none of the 68
patients in arm A achieved CR, whereas of the 71 patients in
arm B, 1 attained CR (%CR, 1.4%). The 1- and 3-year OS
Fig. 1. CONSORT flow diagram of a multicenter
phase II trial of radiotherapy (2 Gy ⁄ fraction, total
dose of 60 Gy) and standard-dose cisplatin and 5-
fluorouracil (SDPF-RT; arm A) or low-dose cisplatin
and 5-fluorouracil (LDPF-RT; arm B) chemotherapy
in esophageal cancer patients with clinical T4
disease and ⁄ or unresectable regional lymph node
metastasis.
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rates were 55.9% and 25.9% in arm A and 56.3% and 25.7%,
respectively, in arm B. The median survival time was
13.1 months for arm A and 14.4 months for arm B. Arm B
was not superior to arm A in terms of OS (hazard ratio, 0.94;
95% CI, 0.64–1.37; Fig. 2).
Discussion
We carried out a randomized phase II study that compared
LDPF-RT (arm B) with SDPF-RT (arm A) for patients with
cT4 or M1Lym esophageal squamous cell carcinoma. Enrol-
ment of patients was planned to continue as phase III if arm B
showed advantages in efficacy and ⁄or toxicity over arm A in
the randomized phase II. However, findings revealed that
LDPF-RT had no advantage over SDPF-RT in terms of effi-
cacy or toxicity, and this study was terminated in the phase II
component.
Although SDPF-RT has been the standard treatment regimen
with modest toxicities for esophageal cancer, a less toxic regi-
men is preferred for more advanced stage cT4 disease.(13–15)
In Japan, LDPF-RT is believed to be less toxic and more
effective, despite insufficient supporting evidence,(16–23)
because LDPF has a theoretical radiosensitizing effect and low
toxicity. Moreover, should adverse effects occur, LDPF can be
stopped immediately. Because of these perceived advantages,
LDPF has begun to prevail in Japan as a treatment for esopha-
geal cancer. Therefore, this study was designed to evaluate the
efficacy and safety of LDPF-RT in patients with locally
advanced, unresectable esophageal cancer.
Our study showed that the primary endpoint of OS was
nearly equivalent in both treatment arms. Therefore, our results
suggest that LDPF-RT had no survival advantage over SDPF-
RT. The 2-year OS of 33.6% in the 139 eligible patients in
this study was close to the 2-year OS (31.5%) reported in our
previous study (JCOG9516) of SDPF.(4) Similarly, the 3-year
OS of 25.9% in the 139 eligible patients in this study was
roughly equivalent to the 3-year OS (approximately 23%)
reported by other studies.(6,24,25) We noted that the treatment
completion rate was slightly higher in arm B (86%) than in
arm A (82%); we speculated that this difference in completion
rate might have been due to the difference in the total dose of
cisplatin, which was slightly lower in arm B (120 mg ⁄m2) than
in arm A (140 mg ⁄m2).
The CR rate in this study was markedly lower than the rate
reported in previous studies;(6,24,25) however, OS was equivalent
between the two treatment arms. JCOG9516 was a phase II trial
of SDPF-RT (the same protocol as arm A in this study) in
patients with cT4 or M1Lym advanced esophageal cancer(4) and
Table 1. Baseline characteristics of patients with unresectable
esophageal squamous cell carcinoma (all randomized; n = 142)
Arm A (n = 71) Arm B (n = 71)
Age, years
Median (range) 63 (37–75) 62 (43–74)
Sex



























†Lower, lower thoracic esophageal cancer; Middle, middle thoracic
esophageal cancer; Upper, upper thoracic esophageal cancer. ECOG,
Eastern Cooperative Oncology Group; PS, performance status; UICC,
Union for International Cancer Control.
Table 2. Proportion of grade 3–4 toxicities during treatment of
patients with unresectable esophageal squamous cell carcinoma with
radiotherapy and standard-dose cisplatin and 5-fluorouracil (arm A)








Leukopenia 18 (26) 15 (21)
Neutropenia 13 (19) 5 (7)
Anemia 10 (14) 4 (6)
Thrombocytopenia 3 (4) 2 (3)
Non-hematologic adverse events
Dysphagia ⁄ esophagitis ⁄ odynophagia 16 (23) 20 (29)
Anorexia 14 (20) 15 (21)
Nausea 6 (9) 2 (3)
Vomiting 2 (3) 0 (0)
Hyponatremia 12 (17) 9 (13)
Infection without neutropenia 6 (9) 9 (13)
Infection with neutropenia 4 (6) 1 (1)
Fistula formation 6 (9) 5 (7)
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Table 3. Proportion of grade 3–4 late toxicities in patients with
unresectable esophageal squamous cell carcinoma treated with
radiotherapy and standard-dose cisplatin and 5-fluorouracil (arm A)
or low-dose cisplatin and 5-fluorouracil (arm B)
Arm A




Fistula formation 12 (18) 15 (22)
Dysphasia ⁄ esophagitis ⁄ odynophagia 7 (11) 7 (10)
Dyspnea 9 (14) 12 (18)
Pneumonitis 6 (9) 6 (9)
Pericarditis 2 (3) 0 (0)
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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demonstrated relatively low %CR (15%) with an acceptable 2-
year survival (31.5%), fairly similar to the rates reported in the
present study. In contrast to the JCOG trials (this study and
JCOG9516), another trial conducted in Japan by Ohtsu et al.(6)
reported a higher %CR (33%) and a nearly equivalent 3-year
survival (23%) compared to the current study. The discrepancy
between the JCOG trials and other trials might be due to
differences in the definitions of CR among these studies.
Regarding toxicity, in this study, LDPF-RT was not associ-
ated with decreased toxicity compared with SDPF-RT.
Although the incidence of hematological toxicity during treat-
ment was low in arm B, there were no significant differences
in the incidences of either non-hematological toxicity or late
toxicities. Finally, there was no significant difference in the
incidence of fistula formation between the two arms. These
findings show that LDPF-RT had no advantage over SDPF-RT
in terms of efficacy and toxicity.
Fistula formation is associated with massive bleeding and
pneumonia and can be the primary cause of treatment-related
death. In this study, esophageal fistulae developed in 15 (21%)
of the 70 treated patients in arm A and 17 (24%) of the 70
treated patients in arm B. This incidence was relatively high
compared to incidences of 9–29% reported in other stud-
ies(6,26–28) involving patients with similar stages of esophageal
cancer. There are two possible explanations for this high rate
of fistula formation. First, data regarding delayed toxicities,
including disease progression, were prospectively collected for
our secondary endpoints. Second, cT4 cancer was defined as a
tumor that invades adjacent organs and is technically impossi-
ble to resect curatively.
Similar to our findings, Sai et al.(29) also concluded that
daily low-dose cisplatin with a continuous infusion of 5-FU
had no advantage over standard-dose cisplatin with 5-FU in
terms of survival, local control, or toxicity. Furthermore, Ni-
shimura et al.(27) maintained that LDPF-RT might have cura-
tive potential, but that this regimen had high toxicity for
patients with cT4 esophageal cancer. Although a certain level
of toxicity inevitably occurs during and after cancer treatment,
a large number of treatment-related deaths is not acceptable.
Results from KROSG0101, a randomized phase II trial com-
paring LDPF-RT to SDPF-RT regimens in clinical stage II–
IVA esophageal cancer patients, also showed that LDPF-RT
was not superior to the SDPF-RT regimen.(30) The 2- and 5-
year overall survival rates for SDPF-RT were 46% and 35%
(95% CI, 22–48%), whereas those for LDPF-RT were 44%
and 22% (95% CI, 11–35%), respectively. Toxicity was similar
in both arms. This means that the efficacy of the PF-RT regi-
men is similar in efficacy and toxicity irrespective of a
method.
Another difficulty with LDPF-RT was that all patients in
arm B required hospitalization at least until the end of the
treatment period because they were receiving continuous infu-
sions of cisplatin and 5-FU. However, 19 (27%) of the 70
patients in arm A could be treated in the outpatient clinic,
except for the period when they received chemotherapy in the
hospital.
In summary, on the basis of this study, we conclude that the
conventional treatment regimen for locally advanced, unresec-
table esophageal cancer should be considered the standard
treatment. Although LDPF-RT prevails in Japan, we have not
been able to identify an obvious advantage for this CRT regi-
men over the SDPF-RT regimen in terms of efficacy, compli-
ance, or toxicity. Therefore, the development of more effective
and safe CRT regimens is necessary.
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